ZD6474(Vandetanib) + Alimta Combo Study

A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Prior Chemotherapy.

The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.

Inclusion Criteria:

• Confirmed advanced or metastatic non-small cell lung cancer
• Failure of first-line chemotherapy
• 1 or more measurable lesion by RECIST

Exclusion Criteria:

• Previous chemotherapy or radiotherapy within 4 weeks
• Significant cardiac events, arrythmias or other cardiac conditions
• Unacceptable laboratory measurements